Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Sonic Healthcare Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $20.17 billion
P/E Ratio 15.55
Dividend Yield 2.14%
Shares Outstanding 478.98 million
Earnings per share 1.982
Dividend per share 0.91
Year To Date Return 34.87%
Earnings Yield 6.43%
Franking 65%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Sonic Healthcare Ltd (ASX: SHL)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
07 Sep 2021 $0.5500 65.00% Final 22 Sep 2021
09 Mar 2021 $0.3600 30.00% Interim 24 Mar 2021
07 Sep 2020 $0.5100 30.00% Final 22 Sep 2020
10 Mar 2020 $0.3400 30.00% Interim 25 Mar 2020
10 Sep 2019 $0.5100 30.00% Final 25 Sep 2019
08 Mar 2019 $0.3300 20.00% Interim 26 Mar 2019
12 Sep 2018 $0.4900 30.00% Final 27 Sep 2018
06 Mar 2018 $0.3200 20.00% Interim 10 Apr 2018
08 Sep 2017 $0.4600 20.00% Final 11 Oct 2017
07 Mar 2017 $0.3100 20.00% Interim 11 Apr 2017
08 Sep 2016 $0.4400 30.00% Final 27 Sep 2016
03 Mar 2016 $0.3000 30.00% Interim 06 Apr 2016
09 Sep 2015 $0.4100 55.00% 22 Oct 2015
06 Mar 2015 $0.2900 55.00% 25 Mar 2015
05 Sep 2014 $0.4000 55.00% Final 23 Sep 2014
03 Sep 2012 $0.3500 45.00% Final 09 Oct 2012
04 Mar 2011 $0.2400 27.92% Interim 24 Mar 2011
08 Sep 2010 $0.3500 35.00% Final 28 Sep 2010
03 Mar 2010 $0.2400 35.00% Interim 25 Mar 2010
08 Sep 2009 $0.3500 35.00% Final 28 Sep 2009
05 Mar 2009 $0.2200 60.00% Interim 26 Mar 2009

SHL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Sonic Healthcare Ltd

Sonic Healthcare is a global pathology provider holding the largest market share positions in Australia, Germany, Switzerland and the U.K., the number two position in Belgium and New Zealand and is the third largest provider in the U.S. Inaddition to pathology laboratories which contribute 85% of revenue, Sonic is a major player in diagnostic imaging and the provision of primary care medical centres in Australia. The company earns 36% of revenue in Australia and New Zealand, 27% in the U.S. and the balance in Europe. Organic growth of the Laboratories segment typically runs between 3% and 5% per year and the company regularly makes acquisitions to enhance its growth.

SHL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $42.12 $-0.33 -0.78% 2,250,022 $42.28 $42.48 $41.91
16 Sep 2021 $42.45 $0.29 0.69% 1,278,994 $42.70 $42.84 $42.23
15 Sep 2021 $42.16 $0.36 0.86% 1,065,015 $41.82 $42.48 $41.74
14 Sep 2021 $41.80 $-0.31 -0.74% 1,066,791 $42.36 $42.36 $41.57
13 Sep 2021 $42.11 $0.48 1.15% 868,511 $41.67 $42.49 $41.67
10 Sep 2021 $41.63 $0.00 0.00% 814,540 $41.90 $41.94 $41.29
09 Sep 2021 $41.63 $-0.12 -0.29% 1,499,518 $41.80 $42.37 $41.47
08 Sep 2021 $41.75 $-0.57 -1.35% 2,166,682 $42.30 $42.53 $41.30
07 Sep 2021 $42.32 $-1.23 -2.82% 1,297,157 $42.83 $43.17 $42.18
06 Sep 2021 $43.55 $-0.20 -0.46% 761,552 $43.72 $43.80 $43.21
03 Sep 2021 $43.75 $0.51 1.18% 882,860 $43.98 $43.98 $43.40
02 Sep 2021 $43.24 $-0.06 -0.14% 1,049,066 $43.71 $43.99 $42.85
01 Sep 2021 $43.30 $-0.10 -0.23% 774,729 $43.21 $43.44 $42.69
31 Aug 2021 $43.40 $0.79 1.85% 2,213,938 $42.85 $43.66 $42.79
30 Aug 2021 $42.61 $-0.11 -0.26% 952,812 $43.95 $43.95 $42.57
27 Aug 2021 $42.72 $0.23 0.54% 1,082,917 $43.40 $43.43 $42.69
26 Aug 2021 $42.49 $0.14 0.33% 796,218 $42.40 $42.67 $42.25
25 Aug 2021 $42.35 $0.14 0.33% 1,046,304 $42.60 $42.84 $42.13
24 Aug 2021 $42.21 $0.56 1.34% 1,064,174 $42.00 $42.69 $41.83
23 Aug 2021 $41.65 $-1.18 -2.76% 1,325,617 $42.75 $42.75 $40.94
20 Aug 2021 $42.83 $0.43 1.01% 1,490,957 $43.00 $43.25 $42.80
19 Aug 2021 $42.40 $0.27 0.64% 1,165,323 $41.90 $42.53 $41.56

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
08 Sep 2021 Christopher Wilks Transfer 73 $3,052,217
As advised by the company. 73,107 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
08 Sep 2021 Christopher Wilks Transfer 73 $3,052,217
As advised by the company. 73,107 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
08 Sep 2021 Colin Goldschmidt Transfer 164 $6,870,338
As advised by the company. 164,559 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
08 Sep 2021 Colin Goldschmidt Transfer 164 $6,870,338
As advised by the company. 164,559 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
07 Sep 2021 Colin Goldschmidt Buy 164 $3,557,765
Exercise of options.
07 Sep 2021 Colin Goldschmidt Exercise 164 $3,557,765
Exercise of options.
07 Sep 2021 Christopher Wilks Exercise 73 $1,580,573
Exercise of options.
07 Sep 2021 Christopher Wilks Issued 73 $1,580,573
Exercise of options.
09 Mar 2021 Christopher Wilks Exercise 2 $81,048
Conversion of securities. 66,111 - performance rights
09 Mar 2021 Christopher Wilks Buy 2 $81,048
Conversion of securities.
09 Mar 2021 Colin Goldschmidt Buy 6 $186,318
Conversion of securities.
09 Mar 2021 Colin Goldschmidt Exercise 6 $186,318
Conversion of securities. 155,980 - performance rights
01 Mar 2021 Kathryn (Kate) Spargo Buy 1 $31,679
On-market trade.
19 Feb 2021 Suzanne Crowe Buy 584 $20,083
On-market trade.
25 Nov 2020 Colin Goldschmidt Issued 50 $1,651,529
Issue of securities. 162,049 - performance rights
25 Nov 2020 Christopher Wilks Issued 19 $629,352
Issue of securities. 68,751 - performance rights
25 Nov 2020 Colin Goldschmidt Issued 381 $12,505,245
Issue of options.
25 Nov 2020 Christopher Wilks Issued 145 $4,765,531
Issue of options.
24 Nov 2020 Christopher Wilks Exercise 19 $637,212
Conversion of securities. 49,540 - performance rights
24 Nov 2020 Christopher Wilks Issued 19 $637,212
Conversion of securities.
24 Nov 2020 Colin Goldschmidt Issued 43 $1,434,268
Conversion of securities.
24 Nov 2020 Colin Goldschmidt Exercise 43 $1,434,268
Conversion of securities. 111,636 - performance rights
23 Sep 2020 Colin Goldschmidt Cancelled 135 $4,608,911
Cancellation of securities.
23 Sep 2020 Colin Goldschmidt Cancelled 17 $599,155
Cancellation of securities. 154,733 - performance rights
23 Sep 2020 Colin Goldschmidt Issued 6 $205,799
Issue of securities. 172,402 - performance rights
23 Sep 2020 Christopher Wilks Issued 2 $89,522
Issue of securities. 76,536 - performance rights
23 Sep 2020 Christopher Wilks Cancelled 60 $2,047,587
Cancellation of securities.
23 Sep 2020 Christopher Wilks Cancelled 7 $266,159
Cancellation of securities. 68,687 - performance rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Christopher David Wilks Chief Financial OfficerFinance Director Dec 1989
Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. He has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a nonexecutive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.
Dr Colin Stephen Goldschmidt Chief Executive OfficerManaging Director Jan 1993
Dr Goldschmidt is the CEO and Managing Director of Sonic Healthcare. He is a qualified medical doctor who then undertook specialist pathology training in Sydney, before gaining his qualification as a specialist pathologist in 1986. Dr Goldschmidt became CEO of Sonic in 1993 and has led Sonic's global expansion by committing the Company to a model of Medical Leadership, which incorporates operational and cultural attributes.
Mr Mark Raymond Compton Non-Executive DirectorNon-Executive Chairman Oct 2014
Prof Compton has senior executive experience in healthcare services. His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. He was also Chief Executive Officer and Managing Director of the formerly ASX-listed companies SciGen Limited and Alpha Healthcare Limited. Prof. Compton has also held a number of non-executive director roles, including for formerly ASX-listed Independent Practitioner Network Limited, Chairman of the Woolcock Institute of Medical Research, nonexecutive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 45 years). In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017, and was appointed as a Member of the Order of Australia (AM) in January 2010.
Dr Phillip James Dubois Executive Director Jul 2001
Dr Dubois is CEO of Sonic's Imaging Division and Chairman of the Sonic Imaging Executive Committee. A neuroradiologist and nuclear imaging specialist, he is currently an Associate Professor of Radiology at the University of Queensland Medical School. He has served on numerous government and craft group bodies, including the councils of the Royal Australian and New Zealand College of Radiologists and the Australian Medical Association, and as Vice-President of the Australian Diagnostic Imaging Association. He is a non-executive Director of Magnetica Limited (since December 2004).
Mr Neville Mitchell Non-Executive Director Sep 2017
Mr Mitchell was Chief Financial Officer and Company Secretary of ASX-listed Cochlear Limited (until March 2017), a medical device developer, manufacturer and seller of hearing devices. Mr Mitchell was a key Member of Cochlear's executive team, responsible for the setting and execution of the company's growth strategy from its listing in 1995 until his resignation. Mr Mitchell currently holds non-executive director roles with ASX-listed healthcare companies Fisher and Paykel Healthcare Corporation Limited (from November 2018) and Osprey Medical Inc. (from July 2012). He is a non-executive Director of QBiotics (from November 2017), an unlisted public company, and a Member of the Australian Board of Taxation. Mr Mitchell was previously a non-executive Director of ASX-listed Sirtex Medical Limited (from April 2017 to September 2018). He has also previously performed roles with a number of industry and government committees, including Chairman of the Group of 100 (Australia's peak body for senior finance executives), and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission (ASIC).
Mr Louis (Lou) James Panaccio Non-Executive Director Jun 2005
Mr Panaccio is a Chartered Accountant with executive management experience in business and healthcare services. Mr Panaccio is currently on the boards of ASX-listed companies Avita Medical Limited (non-executive Chairman from July 2014) and Rhythm Biosciences Limited (non-executive Director from August 2017). He is also a non-executive Director of Unison Housing Limited, Invictus Biopharma Limited and NeuralDx Limited. Mr Panaccio was the Chief Executive Officer and executive Director of Melbourne Pathology (acquired by Sonic in 1999) for 10 years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the executive Chairman of Health Networks Australia until 2017. He was also a non-executive Director of ASX-listed Genera Biosystems Limited from November 2010 until 28 June 2019 (Chairman from July 2011 until 28 June 2019).
Dr Elizabeth Jane Wilson Non-Executive Director Jul 2010
Dr Wilson is an independent non-executive Director with a background in finance, banking and medicine. She is a registered General Medical Practitioner. Dr Wilson is currently a Guardian of the Future Fund, non-executive Director of ASX-listed companies Transurban Group (since January 2017) and Costa Group Holdings Limited (from April 2019), and a non-executive Director of the General Sir John Monash Foundation. She is also Co-Chair of the Australian Government Advisory Board on Technology and Healthcare Competitiveness. Dr Wilson was Deputy Chancellor of the University of Queensland and has previously served on boards of ASX-listed companies, government-owned corporations and not-forprofit companies. Dr Wilson was awarded the 2016 Australian Institute of Company Directors Queensland Gold Medal Award for contribution to business and the wider community.
Professor Suzanne Crowe Non-Executive Director Apr 2020
Professor Crowe has more than 30 years of experience as a clinical researcher. She was an integral part of Burnet's development as a HIV research organisation and held many leadership roles including Program Director, Healthy Ageing and Head of the Centre for Virology. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She was appointed as a Member of the Order of Australia (AM) in 2011 in recognition of her services to medical research in HIV/AIDS medicine and infectious diseases as an academic, clinician and researcher, and to professional associations.
Ms Kathryn (Kate) Dianne Spargo Non-Executive Director Jul 2010
Ms Spargo has gained business experience as both a legal advisor, having worked in private practice and government, and as a director. Ms Spargo has been a director of both listed and unlisted companies over the last 20 years and her current directorships include the ASX-listed companies CIMIC Group Limited (from September 2017), Adairs Limited (from May 2015) and Sigma Healthcare Limited (from December 2015). She is also a non-executive Director of CoInvest Limited, the Future Fuels Cooperative Research Centre, and Geelong Football Club Limited. Ms Spargo was previously a non-executive Director of Fletcher Building Limited (March 2012 to September 2017), UGL Limited (October 2010 to January 2017) and Xenith IP Group Limited (from April 2017 until 15 August 2019).
Mr Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
-
Paul Joseph Alexander Company SecretaryDeputy Chief Financial Officer
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 169,421,519 35.49%
J P Morgan Nominees Australia Pty Limited 77,109,330 16.15%
Citicorp Nominees Pty Limited 28,047,670 5.87%
Jardvan Pty Ltd 15,109,474 3.16%
National Nominees Limited 13,864,108 2.90%
Bnp Paribas Nominees Pty Ltd 7,646,207 1.60%
Bnp Paribas Noms Pty Ltd 7,390,429 1.55%
Argo Investments Limited 3,626,053 0.76%
Australian Foundation Investment Company Limited 3,159,672 0.66%
Polly Pty Ltd 2,817,416 0.59%
Netwealth Investments Limited 2,225,720 0.47%
Citicorp Nominees Pty Limited I 2,209,688 0.46%
Blaise Mentha 2,000,000 0.42%
Hsbc Custody Nominees (Australia) Limited I 1,803,725 0.38%
Australian Executor Trustees Limited 1,681,950 0.35%
Quintal Pty Ltd 1,571,908 0.33%
Hsbc Custody Nominees (Australia) Limited - Gsco Eca 1,429,641 0.30%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd 1,348,393 0.28%
Custodial Services Limited 1,099,321 0.23%
Navigator Australia Lt 1,053,985 0.22%

Profile

since

Note